Streetbeat News

XBIT

XBiotech Inc.

https://www.xbiotech.com

Industry

Biotechnology

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

XBiotech Inc (NASDAQ:XBIT) announced positive data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer, showing improved tolerability and potential survival benefits with its Natrunix antibody in combination with chemotherapy. Despite the positive results, XBIT shares are down 9.54% at $5.50.

Portfolio Pulse from Vandana Singh

June 18, 2024 | 5:08 pm

XBiotech shares are trading higher following the release of positive results from the 1-BETTER study for advanced pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 3:49 pm

XBiotech announced that the primary endpoint for its Phase 2 study was to assess the safety and tolerability of Natrunix when used with the ON+5FU+LV combination. The study found fewer adverse events in the Natrunix arm compared to the placebo, with significantly fewer events in specific categories during the 24-week treatment period.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 3:49 pm

XBiotech (NASDAQ:XBIT) announced promising results from its Phase 1/2 study for advanced pancreatic cancer, showing that its Natrunix antibody, when combined with an established chemotherapy regimen, may improve treatment outcomes and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 3:48 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. MSP Recovery (LIFW) led the gainers with a 23.1% rise, while Aethlon Medical (AEMD) saw the largest decline among the losers, dropping 20.9%. Other notable movers included 60 Degrees (SXTP), Telesis Bio (TBIO), scPharmaceuticals (SCPH), and OpGen (OPGN) with substantial gains, and XBiotech (XBIT), NexImmune (NEXI), Bionomics (BNOX), Senti Biosciences (SNTI), and Celularity (CELU) with notable losses.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 1:06 pm

XBiotech Inc. (NASDAQ:XBIT) has completed enrollment for a Phase I clinical trial for Hutrukin, a novel therapy aimed at reducing brain injury after stroke. The primary objective of the study is to evaluate the safety and pharmacokinetics of Hutrukin in healthy volunteers. Hutrukin is being developed to reduce brain injury following ischemic stroke, a leading cause of disability and death globally. The drug could potentially reduce the inflammatory injuries associated with reperfusion, a phenomenon that occurs during emergency stroke treatment.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:05 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Akanda, VolitionRX, Virpax Pharmaceuticals, Cue Health, Longeveron Inc. - Subscription Right, and AIM ImmunoTech saw increases, while XBiotech, Carmell Therapeutics, Novo Integrated Sciences, EyePoint Pharmaceuticals, Orgenesis, and Yield10 Bioscience experienced decreases.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 9:31 pm

XBiotech Inc. has completed enrollment for the Phase II portion of its 1-BETTER study, a clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. Natrunix is an antibody therapy that binds and neutralizes a substance that causes tumor growth and spread. The Phase II study enrolled 65 subjects to receive either Natrunix in combination with chemotherapy or a placebo. Key endpoints are safety and tolerability, progression-free survival, overall survival, and time-to-treatment-failure.

Portfolio Pulse from Happy Mohamed

August 30, 2023 | 1:08 pm

XBiotech Inc. has started treating the first patient in a phase II clinical study to evaluate Natrunix as a new treatment for Arthritis. The study is double-blind, placebo-controlled, and randomized. Natrunix is a monoclonal antibody that neutralizes the action of interleukin-1, a potent inflammation-causing substance. The study will enroll approximately 210 subjects into three different arms. All subjects will receive methotrexate and be randomized to receive either one of two doses of Natrunix or placebo.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 3:48 pm

Xbiotech announces FDA authorization for a Phase II study of Natrunix in rheumatoid arthritis patients. This marks a significant milestone for the company's drug development program.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.